223 results about "Bronchitic asthma" patented technology

An objective of the present invention is to provide a method of testing for bronchial asthma or chronic obstructive pulmonary disease, a method of screening for candidate compounds for treating bronchial asthma or chronic obstructive pulmonary disease, and a pharmaceutical agent for treating bronchial asthma or chronic obstructive pulmonary disease. The present invention identified genes whose expression levels varied between respiratory epithelial cells that had been stimulated by IL-13 to induce the goblet cell differentiation, and unstimulated respiratory epithelial cells. The respiratory epithelial cells were cultured according to the air interface method. The genes were revealed to be useful as markers for testing for bronchial asthma or chronic obstructive pulmonary disease and screening for therapeutic agents for such diseases. Specifically, the present invention provides methods of testing for bronchial asthma or chronic obstructive pulmonary disease and methods of screening for compounds to treat the diseases based on the comparison of the expression levels of marker genes identified as described above.

An intracellular calcium concentration increase inhibitor containing as the active ingredient (1) a boron compound represented by the formula (I).The compound represented by the formula (I) inhibits the increase of the intracellular calcium concentration, and therefore it is deemed to be useful as an agent for the prophylaxis and / or treatment of platelet aggregation, ischemic diseases in hearts and brains, immune deficiency diseases, allorgosis, bronchial asthma, hypertension, cerebrovascular spasm, various renal diseases, pancreatitis, Alzheimer's disease, etc.

The invention belongs to the technical field of medicine, and particularly relates to an amorphous ambroxol hydrochloride compound and a preparation method thereof. The amorphous ambroxol hydrochloride compound has high purity and stability, does not have obvious moisture absorption and weight increase even under the condition of high humidity, ensures that relative substances do not grow, and has higher dissolution rate than crystalline ambroxol hydrochloride. The invention also relates to an application of the amorphous ambroxol hydrochloride compound in preparation of medicine for the treatment of acute and chronic pulmonary diseases with the symptom of ropy sputum and difficult expectoration, phlegm eliminating treatment of acute exacerbation of chronic bronchitis, asthmatic bronchitis and bronchial asthma, prophylactic treatment of lung complication after an operation, and treatment of infant respiratory distress syndrome (IRDS) of premature infants and neonates.

The invention relates to a medicine for treating bronchitis and bronchial asthma suffered by children aging from three to seven, which is composed of Chinese medicine decoction and acupuncture point injection medicament. The active ingredients of the oral Chinese medicine decoction are composed of various Chinese herbal medicines of roast ephedra, schisandra chinensis, American ginseng, a gecko, zaocys dhumnade, morinda officinalis, lumbricus, semen ginkgo, semen brassicae, semen lepidii, radix pseudostellariae, ramulus cinnamomi, radix paeoniae alba, radix rehmanniae praeparata, fructus psoraleae, radix achyranthis bidentatae, lycium chinense, black ants, poria cocos, largehead atractylodes rhizome, Chinese yam, scorpio, saposhnidoviae radix, cortex magnoliae officinalis, ganoderma lucidum, blackberry lily, Semen cuscutae, cark plum fruit, roast cortex mori radicis, roast flos farfarae, roast radix stemonae, lily, fried almond, tendril-leaved fritillary bulb and the like. The acupuncture point injection medicament is one of nucleotide and casein, placenta tissue fluid or astragalus injection. The medicine can treat both principal and secondary aspects of diseases, perform dialectical therapy, increase immunity of the organism and enable the functions of the damaged lungs, spleens, kidneys and hearts to recover, and has the advantages and effects of high curative rate and no relapse.

The invention discloses a traditional Chinese medicinal composition for treating bronchitis and bronchial asthma. The composition is characterized in that the composition comprises, by weight, 12 parts of Cordyceps sinensis, 15 parts of Radix Codonopsis, 15 parts of Rhizoma Atractylodis Macrocephalae (stir-fried with bran), 15 parts of Poria cocos, 10 parts of Radix Ophiopogonis, 12 parts of Malaytea Scurfpea Fruit (stir-fried with salt), 10 parts of Chinese magnoliavine (processed with vinegar), 12 parts of Chinese angelica, 9 parts of Rhizoma Pinelliae Preparatum, 12 parts of snakegourd peel, 9 parts of bitter apricot kernel, 9 parts of Rhizoma Coptidis, 6 parts of jujube, 10 parts of perilla fruit, 10 parts of Aster tataricus, 10 parts of lily, 6 parts (calcined) gypsum, 9 parts of Cortex Magnoliae Officinalis, 10 parts of Radix Peucedani, 6 parts of dried orange peel, 9 parts of Chinese Eaglewood, 6 parts of ginger, 9 parts of loquat leaf, 10 parts of Fritillaria cirrhosa, 12 parts of prepared rehmannia root, 10 parts of Radix Scrophulariae, 6 parts of Arisaema Cum Bile, 10 parts of Radix Platycodonis, 10 parts of White Mulberry Root-bark (processed with honey), 9 parts of Rhizoma Anemarrhenae, 12 parts of Common Coltsfoot Flower, 15 parts of honeysuckle flower, 12 parts of Herba Schizonepetae, 12 parts of Weeping Forsythia and 6 parts of honey-fried licorice root.

An aromatic compound represented by the following formula or a pharmaceutically acceptable salt thereof:, wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., G1, G2, G3, G4 and G5 are CH or N, X is —NH—, —O—, —CH2—, etc., Y is —CH2—, —CO—, —SO2—, etc., Z is a single bond, —CO—, —SO2—, —NH—, —O—, —S—, —CONH—, —SO2NH—, etc., R2 is hydrogen, alkyl, alkoxy, halogen, etc., and R3 is carbocyclic group, heterocyclic group, alkyl, etc.,is useful as a controlling agent of the function of CCR4 useful for the treatment or therapy for bronchial asthma, atopic dermatitis, etc.

The present invention relates to a compound represented by the formula (I),wherein all symbols are as defined in the description,a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and / or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.

The invention relates to a drug for treating bronchitis and bronchial asthma of 7-15 year old children, which consists of oral Chinese medicinal decoction and acupuncture point injection. The active ingredients of Chinese medicinal decoction consists of a variety of Chinese herbal medicines, comprising Herba Ephedrae Praeparata, Schisandra chinensis, Astragalus mongholicus, American ginseng, Radix Pseudostellariae, a pair of gecko, Zaocys dhumnades, Morinda officinalis, Lumbricus, Herba Epimedii, Sinapis alba, Semen Descurainiae (Lepidium apetalum and / or Descurainia sophia), Ginkgo biloba seed, Ramulus Cinnamomi, Radix Paeoniae Alba, Radix Rehmanniae Praeparata, Fructus Psoralea, Achyranthes bidentata, Fructus Lycii, black ant, Poria cocos, Largehead Atractylodes Rhizome, Rhizoma Dioscoreae, Radix Glycyrrhizae, Scorpion, Divaricate saposhnikovia root, Belamcanda chinensis, Prunus mume, white mulberry root-bark, processed Tussilago farfara flower, Stemona Root, Lily Bulb, Semen Armeniacae Amarum, Ganoderma, Manchurian wildginger, Angelica sinensis, Cornus officinalis and Bombyx Batryticatus (Bombyx mori and / or Beauveria bassiana). The acupuncture point injection is one of nucleotide and casein, placenta tissue fluid and Astragalus mongholicus injection. The drug of the invention can treat both principal and secondary aspects of disease, determine the treatment based on differentiation of symptoms and signs, enhance body immunity, and recover the function of impaired lung, spleen, kidney and heart, and has the advantages of high cure rate and no recurrence.

A Chinese medicine in the form of acupoint paster for preventing and treating bronchial asthma is prepared from asarum herb, Kan-sui root, corydalis tuber and white mustard seed. Its preparing process is also disclosed.

The invention provides a traditional Chinese medicinal preparation for treating a stable phase chronic obstructive pulmonary disease. The traditional Chinese medicinal preparation is prepared from the following medicinal materials in part by weight: 10 to 20 parts of medlar, 3 to 5 parts of prepared common monkshood daughter root, 3 to 5 parts of cinnamon, 10 to 20 parts of malaytea scurfpea fruit, 10 to 20 parts of south dodder seed, 10 to 20 parts of epimedium, 10 to 20 parts of Chinese angelica, 10 to 20 parts of red paeony root, 10 to 20 parts of szechuan lovage rhizome, 10 to 20 parts of root of rehmannia, 10 to 20 parts of amur corktree bark, 10 to 20 parts of white mulberry root bark, 20 to 30 parts of astragalus, 5 to 10 parts of liquoric root, 10 to 20 parts of aster, 5 to 10 parts of dried ginger, 5 to 10 parts of fritillary and 5 to 10 parts of peeled ginkgo seed. The traditional Chinese medicinal preparation can be prepared into formulations such as capsule preparations, granules, tablets, pills, oral liquid preparations and the like. The traditional Chinese medicinal preparation is a pure traditional Chinese medicinal preparation and does not have toxic or side effect. When the medicaments are used together, the traditional Chinese medicinal preparation has the effects of tonifying qi, nourishing yin, warming yang, supplementing lung, invigorating the spleen, nourishing kidney, relieving cough and asthma, eliminating phlegm, and treating both the symptoms and diseases. The traditional Chinese medicinal preparation has the obvious effect of treating the stable-phase chronic obstructive pulmonary disease and has the effect of treating diseases such as bronchial asthma and the like.

The invention discloses a preparation method and a quality control method of a traditional Chinese medicine preparation for treating bronchial asthma, chronic asthmatic bronchitis, emphysema and early pulmonary heart diseases. The preparation method is characterized by being a preparation method of a cough-relieving capsule as a traditional Chinese medicine preparation formed by reforming a cough-relieving tablet, optimization and screening are carried out on an extraction process, and modern new equipment and new method are adopted so as to be suitable for large-scale industrial production; the research on the quality standard is to perfect and improve on the basis of the original standard to establish a perfect method for thin bed identification and content determination so that the quality standard of a product is advanced and controllable, and the clinical effect is ensured.

Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma.

The present invention relates to a kind of medicine composite for treating branchial asthma. The medicine composite consists of active component including salmeterol or its medicinal salt and budesonide in the molar ratio of 1 to 0.38-20, as well as non-active components including solvent, cosolvent, propellant, antioxidant, dilutent and lubricant. The present invention has large range of medicine dosage, long lasting period and high comprehensive effect, and may be prepared into various preparation forms.

The invention discloses Chinese herbal medicine decoction for curing bronchial asthma and a preparation method of the Chinese herbal medicine decoction. The Chinese herbal medicine decoction comprises, by weight, 9-11 parts of sophora japonica leaves, 7-9 parts of cortex lycii radicis, 3-5 parts of amethyst, 1-3 parts of cortex albiziae, 10-12 parts of cordyceps sinensis, 10-20 parts of sugarcane tops, 6-8 parts of human placenta, 8-10 parts of radix stemonae, 5-7 parts of ginseng, 2-4 parts of burdock, 9-11 parts of pomegranate blossom, 10-12 parts of beewax, 4-6 parts of stiff silkworm, 8-10 parts of cacumen biotae, 4-6 parts of fructus psoraleae, 10-15 parts of luffa stems, 3-5 parts of radix ilicis asprellae, 9-11 parts of shaddock peels and 10-12 parts of wild buckwheat. The Chinese herbal medicine decoction for curing bronchial asthma has effects of qi tonifying, lung cleaning, phlegm eliminating, spleen tonifying and qi absorption and is good in curative effect on the bronchitis, short in curing course, non-toxic and free of side effects.

The invention discloses a Bambuterol Hydrochloride oral disintegration tablet, wherein the principal drug employs Bambuterol Hydrochloride, the auxiliary materials include lactose, mannitol, crystalline cellulose, low replacement methylcellulose propylene glycol ether, cross bonding polyvinyl pyrrolidon, sodium hydrogen carbonate, citric acid, Aspartame, perfume compound, and magnesium stearate. The tablet has good treatment action for bronchial asthma, chronic bronchitis and pulmonary emphysema.

The invention relates to the technical field of medicine preparations, in particular to a medicine composition with tiotropium bromide and formoterol, application of the medicine composition and a preparation. The medicine composition comprises the tiotropium bromide or pharmaceutically acceptable salt of the tiotropium bromide and the formoterol or pharmaceutically acceptable salt of the formoterol. The medicine composition with the tiotropium bromide and the formoterol is applied to preparing medicine for treating respiratory and lung inflammatory diseases. The medicine composition is preferably a tiotropium bromide and formoterol composition with synergistic additive effects. The medicine composition, the application and the preparation have the advantages that as proved by pharmacodynamic experiments, the synergistic additive effects can be realized by the tiotropium bromide and the formoterol which are jointly applied, and accordingly bronchiectasis can be forcefully and quickly realized; the medicine composition and the preparation are used for treating the respiratory and lung inflammatory diseases, and preferably used for treating dyspnea such as bronchial asthma and chronic obstructive pulmonary diseases (COPD) due to bronchial constriction.

The present invention provides a prophylactic / therapeutic agent for an allergic disease caused by Th2 cell-polarized activation, which comprises at least one kind selected from a branched amino acid, glycine, serine, arginine, a keto acid thereof and a salt thereof. Because the prophylactic / therapeutic agent of the present invention produces almost no side effects, it can be safely ingested routinely and can be taken for a long time. When the prophylactic / therapeutic agent of the present invention is used in combination with an anti-inflammatory drug, the dose of the anti-inflammatory drug can be reduced. Hence, the prophylactic / therapeutic agent of the present invention is useful for the prevention or treatment of an allergic disease caused by Th2 cell-polarized activation. The prophylactic / therapeutic agent of the present invention is particularly effective on bronchial asthma and pulmonary fibrosis that accompanies bronchial asthma.

The invention discloses a medicine for treating allergic rhinitis and bronchial asthma and a preparation method thereof. The medicine is prepared by decocting aconite and liquorice according to a certain weight ratio, filtering the decoction, concentrating the filtrate, drying the concentrate, grinding the dried concentrate and adding medicinal adjuvants. The medicine is used for treating allergic rhinitis and bronchial asthma, is small in dose and less in medicinal flavor, has high efficacy and safety, low recurrence rate and good long-term efficacy, is low in cost and has good patient compliance.

The invention relates to a levetiracetam sustained release tablet drug composition and quality control and preparation method thereof, in particular to a method for detecting the quality of a levetiracetam sustained release tablet. The method comprises the following steps: determining the content of active component levetiracetam in the levetiracetam sustained release tablet and the content of impurity levetiracetam acid by utilizing a high-performance liquid phase chromatography, wherein the levetiracetam sustained release tablet is formed by a tablet core and a thin-film coating layer covering the surface of the tablet core, and the tablet core comprises levetiracetam, a sustained release skeleton material, a sustained release agent, a flow aid and a lubricating agent. The invention also relates to a pharmaceutical application of the levetiracetam sustained release tablet. The medicinal composition has good pharmaceutical characteristics and can be used for treating or preventing epilepsy, Parkinson disease, dyskinesia, migraine, tremor, essential tremor, bipolar disorder, chronic pain, neuropathic pain, or bronchus, asthma or allergic diseases.

The invention discloses a bronchial asthma treatment drug pillow and belongs to the traditional Chinese medicine technical field. The bronchial asthma treatment drug pillow is formed by the following raw materials of, almonds, dried tangerine or orange peel, platycodon root, honeysuckle, mint, ephedra, cloves, herba periliae, cynanchum glaucescens, ageratum, plaster stone, chrysanthemum, as arum and licorice. According to the bronchial asthma treatment drug pillow, the drug can directly act on the head, the lung can be dispersed, the phlegm can be reduced, the cough can be relieved, and accordingly the effects of lung dispersing, phlegm and pus elimination, spleen and stomach warming for cold dispelling and meridian activating for pain stopping are achieved; the bronchial asthma treatment drug pillow is suitable for the chronic bronchial asthma and the effects on the acute bronchial asthma and bronchitis are also achieved; meanwhile various disadvantages and side effects caused by the traditional treatment method are avoided and the asthma treatment effective rate reaches 98%.

A Chinese medicine for treating bronchopathy, such as bronchitis, bronchial asthma, etc is prepared from 7 Chinese-medicinal materials including loquat leaf, poppy capsule, stemona root, ephedra, etc. Its advantages are high curative effect and no toxic by-effect.

The invention discloses a traditional Chinese medicine for treating bronchial asthma, which is prepared by dispensing a component one with any five to six medicines in a component two, wherein the component one contains 6-10 parts of rhodiola root, 6-10 parts of ligustrum lucidum, 6-10 parts of gynostemma pentaphylla, 6-8 parts of tag, 4-8parts of cinnamon,6-8 parts of radix sophorae falvescentis,6-10 parts of baikal skullcap root, 6-10 parts of earthworm, 6-8 parts of almond, 6-10 parts of brassica alba boiss, 2-8 parts of agilawood,6-12 parts of radix paeoniae alba, 4-8 parts of asarum, 4-8parts of fructus gleditsiae and 2-8 parts of datura flower; the component two contains 6-10 parts of ginseng, 6-10 parts of rhizoma atractylodis, 6-10 parts of PORIA from Yunnan of China, 6-10 partsof root of fangji, 6-8 parts of lepidium seed, 6-10 parts of magnolia officinalis, 6-8 parts of costus root, 6-8 parts of rhizoma zingiberis, 6-8 parts of rhizoma coptidis, 6-10 parts of shizandra berry, 6-10 parts of peucedanum root, 6-10 parts of perilla-seed, 6-10 parts of radish seed, 6-8 parts of liquorice and 6-8 parts of ant. With no toxic and side effect and obvious curative effect, the invention can treat various symptoms, abnormal pathology, physiological change or basic aetiological agent of asthma, fully replace cortical hormone, alleviate the pain of patients, clear away corticalhormone digested by human bodies for a long time and toxin deposited by chemical medicaments, and adjust the internal secretion of the human bodies.

The invention discloses an aconite extract-containing medicinal composition, a preparation method and application thereof. The aconite extract-containing medicinal composition combines the viscera cold primordial qi theory of the six primordial qi theory of 'Kazak Medicine Introduction' which is a traditional medical theoretical basis, and has a main function of removing cold diseases. The Kazak traditional medicament aconite is selected to prepare an external preparation by mixing with white sal-ammoniac (NH4Cl) in proportion through water extraction and ethanol extraction. The preparation includes a medicinal extract and all other external preparations suitable for clinical cold inflammation prevention and treatment. The medicinal compositions has good effect of external auxiliary treatment on bone tuberculosis, scrofula, thyroiditis, rhinitis, bronchial asthma, lumbar disc hernia, rheumatoid arthritis, femoral head necrosis, hyperplasia of mammary glands, hysteromyoma, benign prostatic hyperplasia, osteocarcinoma, psoriasis and the like particularly, has the function of relieving pains and inflammation and the like. The medicinal composition has the advantages of reasonable formula, accurate curative effect, quick response, no irritation and other toxic or side effects, and convenience for preparation.

The invention discloses a traditional Chinese medicinal composition for treating bronchial asthma, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicinal composition is prepared from the following bulk drugs by weight: 30g of astragalus membranaceus, 30g of rhizoma atractylodis macrocephalae, 25g of divaricate saposhnikovia root, 10g of semen brassicae, 10g of honeysuckle, 10g of scutellaria baicalensis, 10g of schisandra chinensis, 10g of raw gypsum, 10g of perilla fruit, 10g of pinellia ternata, 10g of prepared rehmannia, 10g of apricot kernel, 10g of cicada slough, 10g of earthworm, 10g of dried tangerine peel, 6g of bulbus fritillariae cirrhosae, 6g of ephedra, 6g of platycodon grandiflorum, 2g of asarum, 8g of raw ginger, 5g of Chinese date, and 4g of roasted liquorice. The traditional Chinese medicinal composition has the effects on freeing lung and clearing heat, eliminating phlegm and clearing pus, warming middle-jiao and expelling cold, and calming panting and suppressing cough, fundamentally solves medical problems that asthma relapses and cannot be healed after long-time treatment, and can achieve the aim of treating both symptoms and root causes without any side effect.

The invention discloses a traditional Chinese medicine ointment for treating bronchial asthma, and belongs to the field of traditional Chinese medicine preparation, wherein the ointment comprises the following components in parts by weight: 1-10 parts of cordyceps, 5-25 parts of sapogenin, 10-30 parts of semen brassicae, 5-25 parts of aloe, 5-25 parts of dahuricon angelica , 5-25 parts of monkshood, 5-25 parts of pseudostellariae, 5-25 parts of radix aconite agrestis, 5-25 parts of kanziol, 5-25 parts of safflower, 5-25 parts of apricot kernel, 5-25 parts of cassia, 5-25 parts of quispualis, 1-10 parts of white pepper, 5-25 parts of peach kernel, 1-5 parts of fructus garcleniae bornel. This invention has special positive effects on bronchial asthma and the cure rate is high.

The invention belongs to the field of traditional Chinese medicine, and relates to a traditional Chinese medicine preparation used for treating acute bronchitis, chronic bronchitis and bronchial asthma. The invention also relates to a preparation method of the traditional Chinese medicine preparation. The preparation is an oral preparation prepared from raw medicines of lumbricus, dried ginger, baikal skullcap root and rhizoma arisaematis (prepared), which serve as active components of the preparation. The preparation has functions of heat clearing, asthma calming, phlegm dissipating and cough relieving. The compound preparation is prepared with a refined prescription, and accords with a traditional Chinese medical principle that the treatment is determined based on differentiation of symptoms and signs. The preparation has functions of inflammation resisting, infection resisting, phlegm dissipating, spasm relieving, asthma calming, allergy resisting and immunity enhancing. Therefore,the preparation accords with an acute and chronic bronchitis treating principle in modern medical science. The medicinal preparation provided by the invention has advantages of stable quality, small safety side-effect in clinic application, excellent curative effect, and low cost. Also, the preparation is easy to store and to apply.

The invention belongs to the field of biomedicine, and relates to a novel medicinal purpose of a traditional Chinese medicine effective component icariin. The invention specifically relates to a purpose of icariin in the preparation of medicines used for treating bronchial asthma. Test results show that, icariin assists in ameliorating asthma rat lung tissue inflammations, inhibiting inflammatory in asthma rat blood serum, inhibiting inflammatory in asthma rat alveolar lavage fluid, regulating expression unbalance of asthma rat lung tissue Th1 / Th2 relevant cytokine, and regulating expression unbalance of asthma rat lung tissue Th1 / Th2 relevant transcription factor (T-bet / GATA-3). The traditional Chinese medicine effective component icariin provided by the invention can be adopted as an active component, and can be prepared with pharmaceutically acceptable carriers into medicine compositions used for bronchial asthma.

The present invention relates to a kind of medicine for relieving asthma and cough and its preparation process. The medicine of the present invention has Chinese ephedra as chief medicine component, perilla leaf and bupleurum root as adjuvant medicine component, almond, dried orange peel and magnolia bark as assistant medicine components and roasted licorice as guide medicine component. The medicine has determined clinical treating effect, and the functions of promoting lung-Qi flow, relieving asthma, regulating Qi and relieving cough. The medicine may be used in treating cough and asthma caused by wind-cold as well as bronchial asthma and bronchitis.

The invention provides a medicament for treating chronic and intractable lung diseases by acupoint application and summer treatment for winter disease. The medicament is prepared by mixing and grinding white mustard seed, yanhusuo, manchurian wildginger, apricot kernel, processed ephedra herb, common curculigo rhizome and Chinese magnoliavine fruit, and adding fresh ginger juice and honey into the mixture to prepare ointment. The medicament is applied to acupoints in dog days, has definite curative effect of treating winter diseases, has the functions of warming lung and reducing phlegm, nourishing lung and arresting cough, and reinforcing kidney and relieving asthma, and can calm the lung for upper body and reinforce the kidney for the lower body so as to play a role in simultaneously treating principal and subordinate symptoms. By means of the advantages of natural climate, the medicament can fully play the therapeutic effect so as to achieve the effect of getting twice result with half the effort. Clinical effect observation of 86 chronic bronchitis patients, 92 bronchialasthma patients and 102 anaphylacticrhinitis patients proves that the total effective rate of the medicament reaches 91.8 percent, 90.2 percent and 86.2 percent respectively.